Who are Zomiperac's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nevanac, DERACOXIB, NEPA, Xibrom, Yellox.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zomepirac.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Zomiperac — Competitive Intelligence Brief

Zomiperac (ZOMEPIRAC) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: zomepirac. Area: Cardiovascular.

marketed zomepirac Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Zomiperac (ZOMEPIRAC). Zomiperac works by inhibiting the enzyme Prostaglandin G/H synthase 2, which plays a key role in pain and inflammation.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Zomiperac TARGET	ZOMEPIRAC		marketed	zomepirac	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase	1980-01-01
Nevanac	Nevanac	Santa Casa de Misericordia de Santos	marketed		Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase
DERACOXIB	DERACOXIB		marketed		Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase 2; Prostaglandin G/H synthase-2; Uncharacterized protein
NEPA	NEPA	Harrow Eye	marketed		Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase
Xibrom	Xibrom	Bp Consulting, Inc	marketed		Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase
Yellox	Yellox	University of Trieste	phase 3		Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (zomepirac class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zomiperac — Competitive Intelligence Brief. https://druglandscape.com/ci/zomepirac. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab